Video
Breaking Down Treatment Developments in Breast and Genitourinary Cancers From ESMO 2022: Drs O'Shaughnessy and Choueiri
OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
EP: 1.Advances in Breast and Gastrointestinal Cancers at ESMO 2022: Drs Rugo and Abou-Alfa
EP: 2.Gathering Insights in Gynecologic, Lung, and GI Cancers From ESMO 2022: Drs Matulonis, Peters, and Janjigian
EP: 3.Breaking Down Treatment Developments in Breast and Genitourinary Cancers From ESMO 2022: Drs O'Shaughnessy and Choueiri
OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
Today-
We are reporting from the 2022 ESMO Congress!
Get ready for highlights of some of the top news presented each day during the meeting—and soon we’ll speak with Dr Joyce O’Shaughnessy to shed light on important research in breast cancer and Dr Toni Choueiri to provide insight on some of the key highlights in genitourinary cancers.
Welcome to OncLive News Network! I’m Caroline Seymour.
Findings from the phase 3 COSMIC-313 trial showed that treatment with cabozantinib plus nivolumab and ipilimumab resulted in a significant improvement in progression-free survival vs nivolumab and ipilimumab alone in patients with intermediate- or poor-risk advanced renal cell carcinoma. The median PFS was not reached with the triplet and was 11.3 months with the immunotherapy combination alone.
Results from cohort K of the phase 2 EV-103 trial indicated that enfortumab vedotin plus pembrolizumab achieved a high objective response rate and a median duration of response that was not reached as first-line therapy in patients with locally advanced or metastatic cisplatin-ineligible urothelial cancer.
In the AMEERA-3 trial, amcenestrant, an oral selective estrogen receptor degrader, failed to demonstrate a statistically significant improvement in progression-free survival vs treatment of physician’s choice in patients with estrogen receptor-positive, HER2–negative advanced breast cancer who progressed after endocrine-based therapy.
Finally, in results from the phase 3 CodeBreak200 trial, sotorasib demonstrated superior progression-free survival and objective responses compared with docetaxel and had a more favorable safety profile in patients with pretreated KRAS G12C-mutant NSCLC.
Please be sure to check out more of our coverage from the 2022 ESMO Congress at OncLive.com.
That’s all for today.
Thank you for watching OncLive News Network: On Location, I’m Caroline Seymour.
